Invega Hafyera offers patients the fewest doses per year. Phase 3 non-inferiority study results showed over 92% of participants were relapse-free at 12 months
The revenues and profits derived from the new subsidiary will be consolidated in the parent company
The Covid-19 pandemic has exposed the divide that exists between rich and developing nations and to address these challenges the World Health Organisation (WHO), has compiled a list of innovative health technologies that aim to bridge the gap
Self-collection devices designed for ease of use and safety
JADE DARE trial met co-primary and key secondary endpoints and demonstrated a safety profile consistent with previous studies for moderate to severe atopic dermatitis
Advance to Phase 3 follows positive interim Phase 1/2 immunogenicity and safety data. The global clinical trial will evaluate vaccine candidate GBP510 against the AZ/Oxford COVID-19 vaccine
The lab has been developed to aid surgeons to overcome the challenging learning curve to obtain laparoscopic expertise
Results reinforce the well-established safety profile of Dupixent - the first-ever biologic medicine for atopic dermatitis currently approved for patients as young 6 years old
A sum of Rs 70 crores and Rs 10 crores for a new Ayurvedic college in Assam and upgradation of the ayurvedic college in Guwahati respectively
This is Enzene Biosciences third biosimilar to be approved
Subscribe To Our Newsletter & Stay Updated
